Ciclopirox reprograms effector responses and modulates Notch1 activation in activated human T cells.

Consistently, CPX-treated cells demonstrated an increasing trend of CCND3 (cyclin D3), a key regulator of G1/S phase progression in the cell cycle 57 ( Figure S1 C).

also in 63,971 other papers

Furthermore, like CPX, DBZ (0.250 μM) also showed a decreasing trend in Ki-67 expression in CD4 + and CD8 + T cells ( Figure S3 B), suggesting reduced proliferative capacity following Notch inhibition.

also in 47,180 other papers